Industry News
Biotechnology Industry News
After Carisma Therapeutics laid…
After Carisma Therapeutics laid off 95% of its team earlier this year, a Hail Mary merger proposal with another biotech has fallen through.
Biogen has given Alcyone…
Biogen has given Alcyone Therapeutics a starring role in its drug delivery strategy, paying $85 million to buy the biotech and take control of an implant for getting medicines into the spinal canal.
VectorY Therapeutics has seen the…
VectorY Therapeutics has seen the shape of things to come—and it involves finding fresh ways to deliver its gene therapies into the brain.
Having already stripped back their…
Having already stripped back their development plans for the estrogen receptor (ER) degrader vepdegestrant on the back of mixed data, Pfizer and Arvinas have decided to wash their hands of the drug.
Roche dived into the metabolic…
Roche dived into the metabolic dysfunction-associated steatohepatitis space by agreeing to hand over up to $3.5 billion for 89bio and its phase-3-stage candidate.
Beijing QL Biopharmaceutical has…
Beijing QL Biopharmaceutical has shared phase 2 data on its once-monthly GLP-1 candidate, providing early evidence that the ultra-long-acting prospect can match the efficacy of weekly products from Eli Lilly and Novo Nordisk.
One of the top fundraisers of 2024…
One of the top fundraisers of 2024 is halving its workforce about a year after bringing in a $325 million series C. Cell therapy biotech Arsenal Biosciences will lay off 50% of its staff as
Getting a biotech deal done in…
Getting a biotech deal done in 2025 requires more than good science. It’s about the credibility of your story.
California VC firm Aditum Bio is…
California VC firm Aditum Bio is at it again, this time partnering up with China-based Mabwell Bioscience to launch a new biotech focused on cardiovascular disease.
After being touted as a potential…
After being touted as a potential rival to Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu for months, Johnson & Johnson’s IL-23 drug looks like it has a real shot at taking the crown.
Regeneron is racing to regulators…
Regeneron is racing to regulators after reporting a phase 3 win in an ultrarare disease. The biotech plans to file for FDA approval of garetosmab in fibrodysplasia ossificans progressiva by the end of 2025 on
At this year’s meeting of the…
At this year’s meeting of the European Association for the Study of Diabetes in Vienna, Eli Lilly bolstered the case for its oral GLP-1 orforglipron, showing that its pill can both stand on its own
A phase 3 trial of Priovant…
A phase 3 trial of Priovant Therapeutics’ inflammatory disease prospect brepocitinib has hit its primary endpoint, setting the Roivant-backed biotech up to seek FDA approval for the TYK2/JAK1 inhibitor next year.
Sanofi’s head of R&D, Houman…
Sanofi’s head of R&D, Houman Ashrafian, Ph.D., spoke to Fierce days before the company claimed a win for its anti-TNFa/OX40L nanobody in hidradenitis suppurativa.
Innate Pharma is set to lose 30%…
Innate Pharma is set to lose 30% of its employees, including its chief scientific officer, as the French biotech focuses on its “highest-value assets.”
With drugmakers freezing…
With drugmakers freezing investment in the U.K., pharma trade group ABPI has set out its vision for how Scotland can buck the trend and become a leader in R&D and cutting-edge medicines.
During his tenure at Genentech,…
During his tenure at Genentech, ophthalmologist Jason Ehrlich supported the development of Roche’s blockbuster eye disease med Vabysmo. Now, as the co-founder and CEO of newly launched Ollin Biosciences, Ehrlich seeks to topple the titan
Politicians scrambled to arrange…
Politicians scrambled to arrange the committee hearing after a string of Big Pharmas announced moves last week to close R&D sites or pause future funding decisions.
Genmab has dropped an…
Genmab has dropped an antibody-drug conjugate picked up as part of its $1.8 billion ProfoundBio buyout, citing an inadequate benefit-risk profile.
Apollo Therapeutics’ $15 million…
Apollo Therapeutics’ $15 million bet on Avalo’s anti-IL-18 monoclonal antibody appears to have paid off after the candidate aced a phase 2 trial in atopic dermatitis.